Peter Rothschild, President of BioGaia, summarizes the first quarter of 2014 and answers to questions regarding;

  • the new extensive agreement with Nestlé,
  • the development of salen in the US market,
  • upcoming events in the BRIC countries,
  • how the situation in Ukraine and Russia affect the sales,
  • and how the company is affected by the published study showing a neutral effect of L. reuteri Protectis in reducing colic.